Description
Revolade (Eltrombopag) Coated Tablets 25 mg. №28
Ingredients:
- Each coated tablet contains 25 mg of eltrombopag.
Dosage:
- The recommended dose is 25 mg once daily. Dosage may vary based on individual patient needs.
Indications:
- Revolade is indicated for treating thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) and chronic hepatitis C-associated thrombocytopenia.
Contraindications:
- Avoid Revolade if you have a history of hypersensitivity to eltrombopag or any component of the formulation. It is also contraindicated in thrombocytopenia not related to chronic ITP or chronic hepatitis C.
Directions:
- Take Revolade as prescribed by your healthcare provider. Swallow the tablets whole with water, with or without food.
Scientific Evidence:
- Research shows that eltrombopag in Revolade effectively increases platelet counts in chronic ITP patients. Studies in the New England Journal of Medicine confirm its efficacy in maintaining platelet counts and reducing bleeding risk.
Additional Information:
- Monitor liver function tests regularly during Revolade treatment. Contact your healthcare provider if you notice signs of liver problems like jaundice, dark urine, or persistent nausea.
Revolade stimulates platelet production in the bone marrow, raising platelet counts in thrombocytopenia patients. By mimicking thrombopoietin’s action, eltrombopag boosts megakaryocyte differentiation and platelet precursor proliferation.
Clinical trials support Revolade’s efficacy in maintaining platelet counts and reducing the need for other ITP therapies. Compared to traditional treatments, eltrombopag’s once-daily dosing and favorable long-term safety profile make it a convenient option.
